A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

ClinicalTrials.gov ID: NCT07003425

Public ClinicalTrials.gov record NCT07003425. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 11, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.

Study identification

NCT ID: NCT07003425
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Enrollment: 350 participants

Conditions and interventions

Conditions

Atopic Dermatitis

Interventions

APG777 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 13, 2025
Primary completion: Nov 30, 2029
Completion: Nov 30, 2029
Last update posted: Sep 7, 2026

2025 – 2029

United States locations

U.S. sites: 23
U.S. states: 16
U.S. cities: 23

Facility	City	State	ZIP	Site status
Investigational Site	Fountain Valley	California	92708	Recruiting
Investigational Site	Los Angeles	California	90024	Recruiting
Investigational Site	Coral Gables	Florida	33134	Recruiting
Investigational Site	Jacksonville	Florida	32256	Recruiting
Investigational Site	Margate	Florida	33063	Recruiting
Investigational Site	Douglasville	Georgia	30135	Recruiting
Investigational Site	Skokie	Illinois	60077	Recruiting
Investigational Site	Bowling Green	Kentucky	42101	Recruiting
Investigational Site	Rockville	Maryland	20850	Recruiting
Investigational Site	Detroit	Michigan	48202	Recruiting
Investigational Site	Troy	Michigan	48084	Recruiting
Investigational Site	New York	New York	10023	Recruiting
Investigational Site	Wilmington	North Carolina	28403	Recruiting
Investigational Site	Boardman	Ohio	44512	Recruiting
Investigational Site	Mason	Ohio	45040	Recruiting
Investigational Site	Portland	Oregon	97223	Recruiting
Investigational Site	Pittsburgh	Pennsylvania	15213	Recruiting
Investigational Site	Charleston	South Carolina	29425	Recruiting
Investigational Site	Nashville	Tennessee	37215	Recruiting
Investigational Site	Dallas	Texas	75230	Recruiting
Investigational Site	Frisco	Texas	75235	Recruiting
Investigational Site	San Antonio	Texas	78213	Recruiting
Investigational Site	Mill Creek	Washington	98012	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07003425, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 7, 2026 · Synced Sep 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07003425 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →